Drug Profile


Alternative Names: KAD 3213; KMD-3213; KSO-0400; Rapaflo; Silodyx; Thrupas; Urief; Urief OD; Urorec

Latest Information Update: 25 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Kissei Pharmaceutical
  • Developer Actavis; Allergan; Almirall S.A.; Daiichi Sankyo Company; Eisai Co Ltd; JW Pharmaceutical; Kissei Pharmaceutical; Mayne Pharma Group; Pharmaplan; Recordati; Synmosa Biopharma; Zambon France
  • Class Benzamides; Indoles; Muscle relaxants; Small molecules
  • Mechanism of Action Alpha 1a adrenergic-receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Benign prostatic hyperplasia
  • Phase II Urinary calculi
  • Clinical Phase Unknown Nocturia
  • No development reported Prostatitis

Most Recent Events

  • 15 Sep 2017 Launched for Benign prostatic hyperplasia in Australia (PO)
  • 23 May 2017 Registered for Benign prostatic hyperplasia in Australia (PO)
  • 29 Mar 2017 Kissei Pharmaceutical completes a phase III trial in Benign prostatic hyperplasia in Japan (UMIN000018743)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top